Texas Permanent School Fund cut its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Rating) by 7.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,683 shares of the specialty pharmaceutical company’s stock after selling 688 shares during the quarter. Texas Permanent School Fund’s holdings in ANI Pharmaceuticals were worth $279,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Swiss National Bank grew its position in shares of ANI Pharmaceuticals by 9.6% in the second quarter. Swiss National Bank now owns 29,600 shares of the specialty pharmaceutical company’s stock valued at $878,000 after purchasing an additional 2,600 shares during the last quarter. Public Sector Pension Investment Board grew its position in shares of ANI Pharmaceuticals by 2.1% in the second quarter. Public Sector Pension Investment Board now owns 24,249 shares of the specialty pharmaceutical company’s stock valued at $719,000 after purchasing an additional 499 shares during the last quarter. Jackson Creek Investment Advisors LLC acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at approximately $1,120,000. Thompson Siegel & Walmsley LLC grew its position in shares of ANI Pharmaceuticals by 2.8% in the second quarter. Thompson Siegel & Walmsley LLC now owns 435,873 shares of the specialty pharmaceutical company’s stock valued at $12,932,000 after purchasing an additional 11,786 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at approximately $204,000. 67.89% of the stock is currently owned by institutional investors and hedge funds.
ANI Pharmaceuticals Stock Up 2.2 %
Shares of NASDAQ ANIP opened at $43.95 on Tuesday. ANI Pharmaceuticals, Inc. has a 1 year low of $22.31 and a 1 year high of $44.86. The firm’s 50 day moving average price is $39.66 and its 200 day moving average price is $36.37. The firm has a market cap of $767.59 million, a P/E ratio of -9.81 and a beta of 1.03. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.62 and a current ratio of 3.79.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, October 12th. They set a “hold” rating on the stock. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $49.00.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.
- Get a free copy of the StockNews.com research report on ANI Pharmaceuticals (ANIP)
- Michael Burry is Bearish on Stocks Again and Heres Why
- Is Macau a Sinking Ship for Wynn Resorts?
- Don’t Miss These 2 Mid-Cap Techs That Broke Out Last Week
- Why Warner Bros Discovery Is the S&P’s Hottest Stock
- Pinterest is the Social Commerce Platform to Watch in 2023
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.